Improvement of abnormal liver enzymes after rosiglitazone treatment in Chinese type 2 diabetes

Jing Quan Zheng, Kun Wang, Dee Pei, Yen Lin Chen, Yen Lin Chang, Chun Hsien Hsu, Tsan Ming Huang, Mei Yu Lin, Pao Ying Lin, Jiunn Diann Lin

研究成果: 雜誌貢獻文章同行評審

4 引文 斯高帕斯(Scopus)

摘要

Objectives: Insulin resistance is one of the important underlying abnormalities of type 2 diabetes. The effect of thiazolidinedione on liver functions has been controversial in different studies. In this study, we evaluated the effect of rosiglitazone on liver enzymes in subjects with type 2 diabetes with and without abnormal liver function. Materials and Methods: Seventy-three patients with type 2 diabetes taking rosiglitazone 4 mg daily were enrolled in this 3-month study. Forty-two of them had normal liver function (NLF), and 31 had abnormal liver function (ABLF). Blood biochemistries were collected monthly during the treatment period. Results: At baseline, other than age and liver enzymes, there were no differences in body mass index, fasting plasma glucose, hemoglobin A1c (HbA1c), and lipid profiles between the NLF and ABLF groups. At the end of the treatment, HbA1c was lowered in both groups, but only significantly in the ABLF group (P = 0.027). More importantly, serum concentrations of both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in the ABLF group decreased significantly (AST: 57.8 ± 26.5 to 47.5 ± 20.2 U/L, P = 0.006; ALT 66.6 ± 35.0 to 51.9 ± 23.5 UL, P = 0.004), while in the NLF group, a similar change was not found. Conclusion: After 3-month rosiglitazone treatment in subjects with type 2 diabetes with mildly elevated liver enzymes, significant improvement in AST and ALT were observed. Our study provides some hints that rosiglitazone might not be contraindicated in subjects with diabetes with abnormal liver function as previously thought, but further well-designed studies are necessary to clarify this issue.

原文英語
頁(從 - 到)372-376
頁數5
期刊Indian Journal of Pharmacology
44
發行號3
DOIs
出版狀態已發佈 - 六月 2012

ASJC Scopus subject areas

  • 藥理
  • 藥學(醫學)

指紋

深入研究「Improvement of abnormal liver enzymes after rosiglitazone treatment in Chinese type 2 diabetes」主題。共同形成了獨特的指紋。

引用此